A carregar...
Publicação
Dipeptidyl‐peptidase IV inhibitor‐associated bullous pemphigoid efficiently treated with omalizumab
| Nome: | Descrição: | Tamanho: | Formato: | |
|---|---|---|---|---|
| 45.18 MB | Adobe PDF |
Orientador(es)
Resumo(s)
Bullous pemphigoid (BP) is the most common autoimmune blistering disease. High potency topical and/or systemic corticosteroids as well as immunosuppressants are the current mainstay of treatment. However, long-term steroid therapy and systemic immunosuppression may result in significant morbidity and mortality.
Contribution of IgE to BP pathogenesis remains under investigation, but increasing evidence supports a pathogenic significance. Omalizumab is a recombinant humanized monoclonal anti-IgE antibody that has recently emerged as a novel promising treatment alternative for BP.
Descrição
© 2020 Wiley Periodicals LLC.
Palavras-chave
Contexto Educativo
Citação
Dermatol Ther. 2020 Nov;33(6):e14160
Editora
John Wiley & Sons, Inc.